Literature DB >> 16919281

Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o /apoEo mice .

Ella Guy1, Sai Kuchibhotla, Roy Silverstein, Maria Febbraio.   

Abstract

We previously determined that absence of CD36 inhibited atherosclerosis lesion development in 12-week Western diet fed apoE degrees mice, and this was due largely to absence of macrophage CD36. It is possible that at later stages of disease this effect would be lost due to the progressive nature of lesion development and involvement of other factors. However, lesion development continues to be characterized by recruitment of macrophages and foam cell formation, thus it is also possible that delay in lipid accumulation as a result of absence of CD36 would continue to retard lesion development. The objective of this study was to determine if absence of CD36 continued to inhibit lesion formation. Background matched apoE degrees and CD36 degrees /apoE degrees mice were fed a Western diet for up to 35 weeks. At 20 and 35 weeks, lesion area was 25 and 35% less, respectively, in CD36 degrees /apoE degrees mice. Most impressive was the difference in gross appearance of the aortas at 35 weeks: apoE degrees aortas were sclerotic and nearly occluded by lesion, whereas aortas from CD36 degrees /apoE degrees mice had smaller lesions that were more punctate. We conclude that absence of CD36 continues to reduce lesion burden even at late stages of disease in the apoE degrees model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919281     DOI: 10.1016/j.atherosclerosis.2006.07.015

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  33 in total

1.  Vav family Rho guanine nucleotide exchange factors regulate CD36-mediated macrophage foam cell formation.

Authors:  S Ohidar Rahaman; Wojciech Swat; Maria Febbraio; Roy L Silverstein
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 2.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

3.  Targeting Innate Immunity for CV Benefit.

Authors:  Kathryn J Moore; Mason W Freeman
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 4.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 5.  Novel functions of PXR in cardiometabolic disease.

Authors:  Changcheng Zhou
Journal:  Biochim Biophys Acta       Date:  2016-02-26

6.  Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis.

Authors:  Michael J Lipinski; Juan C Frias; Vardan Amirbekian; Karen C Briley-Saebo; Venkatesh Mani; Daniel Samber; Antonio Abbate; Juan Gilberto S Aguinaldo; Davis Massey; Valentin Fuster; George W Vetrovec; Zahi A Fayad
Journal:  JACC Cardiovasc Imaging       Date:  2009-05

Review 7.  PXR: More Than Just a Master Xenobiotic Receptor.

Authors:  Peter O Oladimeji; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2017-11-07       Impact factor: 4.436

Review 8.  CD36: a multi-modal target for acute stroke therapy.

Authors:  Sunghee Cho; Eunhee Kim
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

9.  Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction.

Authors:  Joshua W Knowles; Huijan Wang; Haruka Itakura; Audrey Southwick; Richard M Myers; Carlos Iribarren; Stephen P Fortmann; Alan S Go; Thomas Quertermous; Mark A Hlatky
Journal:  Am Heart J       Date:  2007-12       Impact factor: 4.749

10.  CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury.

Authors:  Eunhee Kim; Aaron T Tolhurst; Lu Ye Qin; Xin-Yuan Chen; Maria Febbraio; Sunghee Cho
Journal:  J Neurosci       Date:  2008-04-30       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.